Evidence map›Paper›PMID 32450899›Full record

ArticleCell communication and signaling : CCS2020

Blocking Connexin-43 mediated hemichannel activity protects against early tubular injury in experimental chronic kidney disease.

Gareth W Price, Christos E Chadjichristos, Panagiotis Kavvadas, Sydney C W Tang, Wai Han Yiu, Colin R Green, Joe A Potter, Eleftherios Siamantouras, Paul E Squires, Claire E Hills

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Inhibition of (interstitial) P2YPflugers Archiv : European journal of physiology · 2026
    Article
  3. Article
  4. Inhibition of (interstitial) P2YResearch square · 2026
    Article
  5. Review
  6. Inhibition of (interstitial) P2YbioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Frontiers in cellular and infection microbiology · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Gareth W PriceJoseph Banks Laboratories, School of Life Sciences, University of Lincoln, Green Lane, Lincoln, UK.
Christos E ChadjichristosNational Institutes for Health and Medical Research Unite Mixte de Recherche S1155, Batiment Recherche, Tenon Hospital, 4 rue de la Chine, 75020, Paris, France.
Panagiotis KavvadasNational Institutes for Health and Medical Research Unite Mixte de Recherche S1155, Batiment Recherche, Tenon Hospital, 4 rue de la Chine, 75020, Paris, France.
Sydney C W TangDivision of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Wai Han YiuDivision of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Colin R GreenDepartment of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand.
Joe A PotterJoseph Banks Laboratories, School of Life Sciences, University of Lincoln, Green Lane, Lincoln, UK.
Eleftherios SiamantourasJoseph Banks Laboratories, School of Life Sciences, University of Lincoln, Green Lane, Lincoln, UK.
Paul E SquiresJoseph Banks Laboratories, School of Life Sciences, University of Lincoln, Green Lane, Lincoln, UK.
Claire E HillsJoseph Banks Laboratories, School of Life Sciences, University of Lincoln, Green Lane, Lincoln, UK. chills@lincoln.ac.uk.
University of Lincoln · GBUniversity of Hong Kong · HKAssistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTubulointerstitial fibrosis represents the key underlying pathology of Chronic Kidney Disease (CKD), yet treatment options remain limited. In this study, we investigated the role of connexin43 (Cx43) hemichannel-mediated adenosine triphosphate (ATP) release in purinergic-mediated disassembly of adherens and tight junction complexes in early tubular injury.

methodsHuman primary proximal tubule epithelial cells (hPTECs) and clonal tubular epithelial cells (HK2) were treated with Transforming Growth Factor Beta1 (TGF-β1) ± apyrase, or ATPγS for 48 h. For inhibitor studies, cells were co-incubated with Cx43 mimetic Peptide 5, or purinergic receptor antagonists Suramin, A438079 or A804598. Immunoblotting, single-cell force spectroscopy and trans-epithelial electrical resistance assessed protein expression, cell-cell adhesion and paracellular permeability. Carboxyfluorescein uptake and biosensing measured hemichannel activity and real-time ATP release, whilst a heterozygous Cx43

resultsImmunohistochemistry of biopsy material from patients with diabetic nephropathy confirmed increased expression of purinergic receptor P2X7. TGF-β1 increased Cx43 mediated hemichannel activity and ATP release in hPTECs and HK2 cells. The cytokine reduced maximum unbinding forces and reduced cell-cell adhesion, which translated to increased paracellular permeability. Changes were reversed when cells were co-incubated with either Peptide 5 or P2-purinoceptor inhibitors. Cx43

conclusionData suggest that Cx43 mediated ATP release represents an initial trigger in early tubular injury via its actions on the adherens and tight junction complex. Since Cx43 is highly expressed in nephropathy, it represents a novel target for intervention of tubulointerstitial fibrosis in CKD. Video Abstract In proximal tubular epithelial cells (PTECs), tight junction proteins, including zona occuludens-1 (ZO-1), contribute to epithelial integrity, whilst the adherens junction protein epithelial (E)-cadherin (ECAD) maintains cell-cell coupling, facilitating connexin 43 (Cx43) gap junction-mediated intercellular communication (GJIC) and the direct transfer of small molecules and ions between cells. In disease, such as diabetic nephropathy, the pro-fibrotic cytokine transforming growth factor beta1 (TGF-β1) binds to its receptor and recruits SMAD2/3 signalling ahead of changes in gene transcription and up-regulation of Cx43-mediated hemichannels (HC). Uncoupled hemichannels permit the release of adenosine triphosphate (ATP) in to the extracellular space (↑[ATP]

Indexed as

Kidney TubulesAdenosine TriphosphateAnimalsCell AdhesionCell LineConnexin 43HumansMiceMiddle AgedRenal Insufficiency, ChronicAdenosine TriphosphateConnexin 43GJA1 protein, humanATPCell adhesionChronic kidney diseaseConnexinsHemichannelsTubular injury

Identifiers

PMID32450899
PMCPMC7249671
OpenAlexW3031051879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.